JAKOB BRIX CHRISTENSEN

CFO
MANAGEMENT
Bioporto
Denmark

Business Expert Nephrology
Biography

Mr. Jakob Brix Christensen has been appointed CFO of BioPorto from January 1, 2016. Jakob has more than 10 years’ experience from financial management positions within medtech/life-science companies in Denmark and US. Mr. Jakob Brix Christensen was previously member of the management team of Novozymes Biopharma (now Albumedix a/s) and before that Director of Investor Relations and US CFO at Origio. In addition to that Mr. Jakob Brix Christensen has been with GN Resound, Handelsbanken Capital Markets and Ernst&Young. Mr. Jakob Brix Christensen holds an MSc in Economics and Business administration from Aarhus Business School and a Graduate Diploma in Financial and Management Accounting (HD-R), supplemented by management training at Richmond University and Chicago Booth School of Business.

Research Intrest

  Financial management